Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 18/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | BCL2L11 | O43521 | 11/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22975719 | 0.88 | MCL1 (0.61) | MCL1SIGMAR1BCL2L11 | |
| SCHEMBL22975683 | 0.87 | MCL1 (0.45) | MCL1SIGMAR1BCL2L11CCND1 | |
| SCHEMBL22975994 | 0.85 | MCL1 (0.49) | MCL1BCL2L11 | |
| SCHEMBL22975995 | 0.85 | MCL1 (0.49) | MCL1BCL2L11 | |
| SCHEMBL24461727 | 0.84 | MCL1 (0.42) | MCL1SIGMAR1BCL2L11CCND1 | |
| SCHEMBL25670137 | 0.84 | MCL1 (0.42) | MCL1SIGMAR1BCL2L11CCND1 | |
| SCHEMBL25813892 | 0.84 | MCL1 (0.42) | MCL1SIGMAR1BCL2L11CCND1 | |
| SCHEMBL22894800 | 0.84 | MCL1 (0.42) | MCL1SIGMAR1BCL2L11CCND1 | |
| SCHEMBL29414585 | 0.84 | MCL1 (0.42) | MCL1SIGMAR1BCL2L11CCND1 | |
| SCHEMBL17542341 | 0.83 | MCL1 (0.58) | MCL1BCL2L11CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762393-B1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | AMGEN INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210047344-A1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210047344-A1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC. (US) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047344-A1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | MCL1, BCL2A1, BCLAF1 | MCL1 1/4885SIGMAR1 440/4885BCL2L11 7/4885 |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | MCL1, BCL2A1, BCLAF1 | MCL1 1/4885SIGMAR1 440/4885BCL2L11 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.